AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9373656
Drug: 5 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 days treatment with Quinimax® (10 mg/kg twice daily)
Trial: 9373656
Drug: 7 days
RxNorm normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 days treatment with Quinimax® (10 mg/kg twice daily)
Trial: 23050526
Drug: Policy implementation
RxNorm normalized name: Polivy
DrugBank: Polatuzumab vedotin (DB12240)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Policy implementation (discontinuation of additional payments for preventable infections)
Trial: 18511530
Drug: Intraarticular corticosteroid
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarticular corticosteroid (1 mL, 40 mg methylprednisolone acetate) followed by a 12‐week comprehensive home exercise programme
Trial: 18511530
Drug: Intraarticular serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarticular serum physiologic (1 mL solution of 0.9% sodium chloride) followed by a 12‐week comprehensive home exercise programme
Trial: 9049962
Drug: Intensive chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive chemotherapy (CCG-1800 series, 1989-1994)
Trial: 9049962
Drug: Moderate intensity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate intensity chemotherapy (CCG-100 series, 1983-1989)
Trial: 6129091
Drug: Pafenolol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pafenolol (5 mg)
Trial: 6129091
Drug: Pafenolol (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pafenolol (7.5 mg)
Trial: 6129091
Drug: Metoprolol (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (15 mg)
Trial: 6129091
Drug: Terbutaline (inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline (inhaled in increasing doses)
Trial: 24332587
Drug: Supraperiosteal injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supraperiosteal injection of methylprednisolone
Trial: 24332587
Drug: Oral tablets
RxNorm normalized name: digoxin 0.1875 MG Oral Tablets
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tablets of methylprednisolone
Trial: 24332587
Drug: Intravenous (i.v.)
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (i.v.) injection of methylprednisolone
Trial: 11093967
Drug: Red wine
RxNorm normalized name: Red wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red wine (60 g ethanol) with a standard dinner
Trial: 6356605
Drug: Verbascan (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verbascan (10 mg three times daily)
Trial: 25669832
Drug: Concurrent regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent regimen with gefitinib (250 mg) and carboplatin/pemetrexed (AUC = 6 and 500 mg/m2; 3-weekly)
Trial: 25669832
Drug: Sequential alternating
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential alternating regimen with gefitinib (250 mg) and carboplatin/pemetrexed (AUC = 6 and 500 mg/m2; 3-weekly)
Trial: 21811060
Drug: Pomegranate juice
RxNorm normalized name: pomegranate juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomegranate juice (120 ml)
Trial: 16796705
Drug: Levodopa (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa (100 mg single dose)
Trial: 26953770
Drug: Balloon Rectal
RxNorm normalized name: CATHETER,BALLOON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balloon Rectal Channel Catheter (BRCC)
Trial: 24530403
Drug: AV7909 with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AV7909 with low-dose (0.25mg/dose) CPG 7909
Trial: 24530403
Drug: AVA (Anthrax
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVA (Anthrax Vaccine Adsorbed, no CPG 7909)
Trial: 20412605
Drug: Multiple-micronutrient supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-micronutrient supplementation (20 mg Fe and 400 microg folic acid)
Trial: 18603822
Drug: Acarbose 300
RxNorm normalized name: Acarbose
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acarbose 300 mg/day for 12 months
Trial: 15823212
Drug: Interferon-alpha 6
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha 6 million units (6-MU) thrice weekly for 24 weeks
Trial: 15823212
Drug: Interferon-alpha 3
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha 3 million units (3-MU) thrice weekly for 24 weeks
Trial: 12377843
Drug: Inhaled flunisolide
RxNorm normalized name: flunisolide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled flunisolide via metered‐dose inhaler (250 micro g per activation) eight puffs bid
Trial: 10357386
Drug: ddC/ZDV (zalcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ddC/ZDV (zalcitabine 0.75 mg and zidovudine 200 mg every 8 h)
Trial: 10357386
Drug: SQV/ZDV (saquinavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQV/ZDV (saquinavir 600 mg and zidovudine 200 mg every 8 h)
Trial: 10357386
Drug: SQV/ddC/ZDV (saquinavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQV/ddC/ZDV (saquinavir 600 mg, zalcitabine 0.75 mg and zidovudine 200 mg every 8 h)
Trial: 7584529
Drug: 50 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 micrograms ovine CRH administered intravenously as a bolus every hour from 0.00 hrs. to 6.00 hrs.
Trial: 31490257
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine (1.5 mg/kg bolus dose followed by a 2 mg/kg/h continuous infusion during the intraoperative period, continued for 1 hour postsurgery)
Trial: 24610631
Drug: Low-dose iloprost
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose iloprost (30 ng/kg/min)
Trial: 24610631
Drug: High-dose iloprost
RxNorm normalized name: Iloprost
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose iloprost (50 ng/kg/min)
Trial: 21448165
Drug: sorafenib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sorafenib plus IL‐2 (400 mg twice daily + 4.5 MIU five times per week for 6 in every 8 weeks)
Trial: 21448165
Drug: sorafenib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sorafenib plus IL‐2 (initial higher dose)
Trial: 15208494
Drug: Radioiodine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radioiodine therapy (400 MBq)
Trial: 9494430
Drug: Water-cooled jacket
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water-cooled jacket with inlet water temperature maintained at 10-12 degrees C and flow rates of 2.6 +/- 0.3, 4.3 +/- 0.3, and 5.1 +/- 0.3 l/h.
Trial: 2847522
Drug: Enalaprilat (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalaprilat (1.25 or 5.0 mg)
Trial: 2847522
Drug: Furosemide (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (40 or 80 mg)
Trial: 30866895
Drug: Personalised texting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalised texting intervention (CRA summary letter + 24 weekly personalised text messages)
Trial: 30866895
Drug: Non-personalised texting
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-personalised texting intervention (non-personalised letter + 24 weekly non-personalised text messages)
Trial: 28337893
Drug: Symbiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symbiotic treatment (Lactobacillus acidophilus NCFM, Bifidobacterium lactis, and fructo‐oligosaccharides) as adjunctive therapy
Trial: 28337893
Drug: Standard pharmacological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard pharmacological treatment (nasal corticosteroid, oral antihistamine, and isotonic saline)
Trial: 10779420
Drug: Subcutaneous bolus
RxNorm normalized name: subcutaneous bolus insulin patch pump, 200 unit, disposable 2 unit MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous bolus injection of deferoxamine
Trial: 10779420
Drug: Subcutaneous continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous continuous infusion of deferoxamine
Trial: 10779420
Drug: Long-term efficacy
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term efficacy of bolus injection
Trial: 1594552
Drug: Pancrex M
RxNorm normalized name: Coenzyme M
DrugBank: Coenzyme M (DB09110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancrex M (newer microsphere preparation)
Trial: 3976336
Drug: Naloxone (0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (0.01 mg/kg, i.m.)
Trial: 31347692
Drug: Control (FeSO4,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (FeSO4, 60 mg Fe/kg)
Trial: 28531643
Drug: LNS (lipid-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LNS (lipid-based nutrient supplements)
Trial: 28531643
Drug: LNS-VM (lipid-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LNS-VM (lipid-based nutrient supplements with vitamins and minerals)
Trial: 24695878
Drug: Fluoroscopic cervical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoroscopic cervical paramidline interlaminar epidural steroid injection (ESI)
Trial: 22278649
Drug: High-intensity stretch
RxNorm normalized name: Mederma Stretch Mark Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity stretch home mechanical therapy (n = 11)
Trial: 22278649
Drug: Low-intensity stretch
RxNorm normalized name: Mederma Stretch Mark Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity stretch home mechanical therapy (n = 9)
Trial: 12586131
Drug: Aspirin bolus
RxNorm normalized name: ASPIRIN 16 g ORAL TABLET [Aspirin Bolus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin bolus (500 mg)
Trial: 12586131
Drug: Ticlopidin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticlopidin (500 mg loading dose)
Trial: 367795
Drug: Paracetamol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (0.5 g X 4 for 3 days)
Trial: 367795
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (0.5 g X 4 for 3 days)
Trial: 31606939
Drug: Continuous NB‐UVB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous NB‐UVB therapy (Side A)
Trial: 31606939
Drug: Interrupted NB‐UVB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interrupted NB‐UVB therapy (Side B)
Trial: 31606939
Drug: Continuous NB‐UVB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous NB‐UVB treatment (Group 2)
Trial: 31606939
Drug: Interrupted NB‐UVB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interrupted NB‐UVB treatment (Group 3)
Trial: 27189212
Drug: Bosentan dosing
RxNorm normalized name: Bosentan
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bosentan dosing regimen
Trial: 22170367
Drug: caffeine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: caffeine (3 mg caffeine/kg)
Trial: 17696221
Drug: Current and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current and emerging therapies for HRS
Trial: 15827365
Drug: Topical glyceryl
RxNorm normalized name: glyceryl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical glyceryl trinitrate (1.25 mg/24-h)
Trial: 10540564
Drug: Inhaled formoterol
RxNorm normalized name: formoterol Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled formoterol (dry powder with ISF system) 12 mcg twice daily
Trial: 10540564
Drug: Salbutamol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (200 mg qid)
Trial: 8535647
Drug: Combination studies
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination studies and meta-analyses
Trial: 7032291
Drug: Verapamil (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (80 mg every 6 hours)
Trial: 7032291
Drug: Verapamil (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (120 mg every 6 hours)
Trial: 28741044
Drug: Asenapine (5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asenapine (5-10 mg/day)
Trial: 28741044
Drug: Olanzapine (5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (5-10 mg/day)
Trial: 22260818
Drug: Oral clodronate
RxNorm normalized name: Clodronic acid
DrugBank: Clodronic acid (DB00720)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral clodronate 1600 mg daily
Trial: 22260818
Drug: Anti‐rheumatic therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti‐rheumatic therapy alone
Trial: 16330884
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone substitution in GH‐deficient patients
Trial: 12000778
Drug: DOTS without
RxNorm normalized name: D3 Dots
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DOTS without direct observation (self-administered)
Trial: 9798134
Drug: 7-day estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day estrogen matrix patch (Climara) at 0.5 mg/day
Trial: 9798134
Drug: 7-day estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day estrogen matrix patch (Climara) at 0.1 mg/day
Trial: 9798134
Drug: 0.625-mg/day oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625-mg/day oral conjugated equine estrogen
Trial: 9798134
Drug: 7-day estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day estrogen patch
Trial: 6996120
Drug: sotalol 160
RxNorm normalized name: sotalol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sotalol 160 - 800 mg
Trial: 6996120
Drug: atenolol 100
RxNorm normalized name: atenolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atenolol 100 - 500 mg
Trial: 17644623
Drug: Hypertension and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertension and diabetes medications (in women)
Trial: 10979113
Drug: Niacin (3000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niacin (3000 mg/d)
Trial: 6322709
Drug: Cimetidine, 1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine, 1,200 mg/day
Trial: 6322709
Drug: Cimetidine, 2,400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine, 2,400 mg/day
Trial: 6322709
Drug: Ranitidine, 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine, 300 mg/day
Trial: 30875247
Drug: Azithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (500 mg oral, thrice weekly for 48 weeks)
Trial: 28025189
Drug: Cardiopoietic cells
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiopoietic cells in patients with baseline left ventricular end-diastolic volume 200-370 mL (60% of patients)
Trial: 26292180
Drug: Total glucosides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total glucosides of paeony (TGP) 1.8 g/day combined with Methotrexate (MTX) 10 mg/week plus Leflunomide (LEF) 20 mg/day
Trial: 26292180
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no TGP) with Methotrexate (MTX) 10 mg/week plus Leflunomide (LEF) 20 mg/day
Trial: 21535424
Drug: Group cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive behavioural therapy (CBT) for first-episode psychosis participants (n = 25)
Trial: 21535424
Drug: Group cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive behavioural therapy (CBT) for stable psychosis patients (n = 15)
Trial: 17123219
Drug: Specific aftercare
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific aftercare measures after inpatient therapy
Trial: 8387177
Drug: Neoadjuvant MVP
RxNorm normalized name: MVP-S
DrugBank: Maveropepimut-S (DB17339)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant MVP (mitomycin, vindesine/vinblastine, higher-dose cisplatin)
Trial: 3500381
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily tobramycin (5.1 mg/kg/day for 9 days)
Trial: 3500381
Drug: Thrice daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice daily tobramycin (5.1 mg/kg/day for 9 days)
Trial: 29095725
Drug: Guided Internet-Based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided Internet-Based Cognitive Behavior Therapy (iCBT) for tinnitus over 8 weeks
Trial: 29095725
Drug: Weekly monitoring
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly monitoring (control group)
Trial: 12641503
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 (1000 IU) and calcium citrate (800 mg) daily (group A)
Trial: 12641503
Drug: Sodium fluoride
RxNorm normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium fluoride (25 mg b.d., group B)
Trial: 12641503
Drug: Intravenous ibandronate
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ibandronate (1 mg every 3 months, group C)
Trial: 30780196
Drug: Vortioxetine combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine combined with cognitive behaviour intervention therapy
Trial: 27419388
Drug: High intensity
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High intensity aerobic exercise program (3 times weekly for 4 months on a bicycle ergometer at 60-70% heart rate reserve)
Trial: 22682213
Drug: Treatment received
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment received during the trial
Trial: 19733016
Drug: Postoperative continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative continuous accelerated irradiation (p‐CAIR) therapy
Trial: 19733016
Drug: Postoperative conventional
RxNorm normalized name: ENSURE SURGERY PERIOPERATIVE KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative conventional fractionation (p‐CF) therapy
Trial: 11756862
Drug: Avonex treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avonex treatment
Trial: 9370894
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (20 mg elemental zinc per day)
Trial: 4043200
Drug: Piretanide treatment
RxNorm normalized name: piretanide
DrugBank: Piretanide (DB02925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piretanide treatment in patients with ascites
Trial: 4043200
Drug: Piretanide treatment
RxNorm normalized name: piretanide
DrugBank: Piretanide (DB02925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piretanide treatment after resolution of ascites
Trial: 4043200
Drug: Piretanide treatment
RxNorm normalized name: piretanide
DrugBank: Piretanide (DB02925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piretanide treatment in patients with diuretic resistant ascites
Trial: 4043200
Drug: Piretanide treatment
RxNorm normalized name: piretanide
DrugBank: Piretanide (DB02925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piretanide treatment in patients with gross ascites
Trial: 27521483
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose radiation (LDR)
Trial: 12574564
Drug: NXY-059 915
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NXY-059 915 mg over 1 hour followed by 420 mg/h for 71 hours
Trial: 12574564
Drug: NXY-059 1820
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NXY-059 1820 mg for 1 hour followed by 844 mg/h for 71 hours
Trial: 12148471
Drug: Chlormadinone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlormadinone (2 mg/day for 5 days every month)
Trial: 12148471
Drug: Ethinylestradiol 35
RxNorm normalized name: Ethinylestradiol 35 microgram and norethisterone 1 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethinylestradiol 35 micrograms plus desogestrel 150 mg (21 days every month)
Trial: 2179857
Drug: Conjugate vaccine
RxNorm normalized name: meningococcal conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjugate vaccine prepared by covalently coupling the H influenzae type b capsular polysaccharide with a protein carrier antigen, administered at 3, 4, and 6 months of age.
Trial: 2179857
Drug: Conjugate vaccine
RxNorm normalized name: meningococcal conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjugate vaccine prepared by covalently coupling the H influenzae type b capsular polysaccharide with a protein carrier antigen.
Trial: 7398002
Drug: Persantine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Persantine plus aspirin (PR/A)
Trial: 27568513
Drug: Oral methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral methadone treatment
Trial: 22037139
Drug: Daily tDCS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily tDCS sessions
Trial: 22037139
Drug: Second daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second daily tDCS sessions
Trial: 16180627
Drug: Dopamine receptor
RxNorm normalized name: Dopamine receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine receptor agonist bromocriptine